Trial Profile

Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

13 Jan 2025 Status changed from active, no longer recruiting to completed.
06 Dec 2023 Planned End Date changed from 30 Nov 2023 to 31 Mar 2024.
06 Jun 2023 Results (n=41) assessing the efficacy and safety of nivolumab in patients with intermediate-high risk P16+ oropharynx cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com